Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00345618 · ClinicalTrials.gov registry record · Phase 3
Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,202
- Enrollment target
NCT00345618: Completed Phase 3 study, sponsored by Sanofi.
NCT00345618 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 3,202 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (315% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00345618, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,202 participants
- Enrollment target
Study Summary
Objectives are to evaluate whether idrabiotaparinux sodium (SSR126517E) is as least as effective as a standard warfarin treatment to prevent recurrence of venous thromboembolic events (VTE) in patients with symptomatic pulmonary embolism (PE) with or without symptomatic deep venous thrombosis (DVT) and to assess its safety (bleedings) versus warfarin.
Interventions
- DRUG Warfarin
- DRUG Idrabiotaparinux sodium
- DRUG Avidin
- DRUG Placebo (for idrabiotaparinux sodium)
- DRUG Placebo (for warfarin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,202 participants |
| Start Date | 2006-06 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
What the finished NCT00345618 record still lists
NCT00345618 is an interventional study that assigns participants to a tested intervention. Its 3,202 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (315% higher).
The record links to 0 conditions, and to 5 interventions - of which Warfarin is the first listed.
NCT00345618 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00345618 about?
NCT00345618 is a clinical study titled "Clinical Study Assessing Idrabiotaparinux Sodium Injections Once-weekly in Pulmonary Embolism Therapeutic Approach". Objectives are to evaluate whether idrabiotaparinux sodium (SSR126517E) is as least as effective as a standard warfarin treatment to prevent recurrence of venous thromboembolic events (VTE) in patients with symptomatic pulmonary embolism (PE) with or without symptomatic deep venous thrombosis (DVT) ...
What is the current status of trial NCT00345618?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,202 participants. The study started on 2006-06. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00345618?
The interventions under investigation include: Warfarin (DRUG), Idrabiotaparinux sodium (DRUG), Avidin (DRUG), Placebo (for idrabiotaparinux sodium) (DRUG), Placebo (for warfarin) (DRUG).
Who is sponsoring clinical trial NCT00345618?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00345618's enrollment target sits among peer trials
3,202 73rd of 2000 higher than 1,928 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02043457 · 3,200 participants
Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance
- NCT04045665 · 3,200 participants · Phase 3
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
- NCT05381766 · 3,200 participants · NA
Building Access to Food Through Systems and Solidarity
- NCT06042543 · 3,200 participants · NA
Novel, One Stop, Affordable, Point of Care and AI Supported System of Screening, Triage and Treatment Selection for Cervical Cancer in LMICs
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia